• Why choose Olink for targeted protein biomarker discovery?

    • High quality data that you can trust
    • The rapid high throughput analysis that your studies deserve
    • The most effective use of your precious samples
  • Proseek multiplex for protein biomarker discovery

Testimonials

  • We are impressed by the quality of data delivered by the Olink technology with very small sample sizes. The application in the field of precision medicine is extremely promising.

    Professor Mathias Uhlen, Science for Life Laboratory & Royal Institute of Technology (KTH), Stockholm
  • Olink's Immunoassay panels are very useful tools for targeting and discovering protein dynamics in our longitudinal studies, such as the integrative personal omics profile (iPOP).

    Professor Mike Snyder, Department of Genetics, Stanford University
  • Olink’s multiplex immunoassay panels are unique tools for finding new biomarkers and gaining a better understanding of the pathophysiology of diseases, which is something I apply in my own field of pain research.

    Professor Torsten Gordh, Department of Surgical Sciences, Uppsala University
  • Olink’s 92-plex Immuno-Oncology panel offers a unique compilation of molecules that play key roles in immunotherapeutic treatments. Miniaturization of the assay to use only 1 µL of sample is a significant advantage for clinical studies with limited amounts of biospecimens.

    Assistant Professor Seunghee Kim-Schulze, Mount Sinai School of Medicine NY.

Latest product news (Feb 2017)

Extending our flexible, proteomics-scale solution for targeted protein biomarker discovery!

With the launch of three new Cardiometabolic, Cell Regualtion and Development panels , we can now offer 981 high-quality protein assays. These new panels are focused on key biological processes with broad clinical relevance and will enable scientists to further probe the complexities of the human plasma proteome.

Share in our company vision!

View the video and see where Olink Proteomics is today (at the forefront of targeted protein biomarker discovery), and where we see our future, in the development  of precision diagnostics and the realization of precision medicine.